Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name CHEK1 positive
Gene Variant Detail

CHEK1 positive (unknown)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
CHEK1 positive head and neck squamous cell carcinoma sensitive CCT244747 + Radiotherapy Preclinical - Cell culture Actionable In a preclinical study, CCT244747 inhibited Chek1 activation, resulted in sensitizing head and neck squamous cell carcinoma cell lines to radiation treatment in culture (PMID: 27422809). 27422809
CHEK1 positive head and neck squamous cell carcinoma sensitive CCT244747 + Paclitaxel + Radiotherapy Preclinical - Cell line xenograft Actionable In a preclinical study, CCT244747, Taxol (paclitaxel), and radiation triple therapy synergistically inhibited Chek1 activation, and resulted in growth inhibition of head and neck squamous cell carcinoma cell lines in culture and in cell line xenograft models (PMID: 27422809). 27422809
CHEK1 positive lung non-small cell carcinoma predicted - sensitive Prexasertib Preclinical - Cell line xenograft Actionable In a preclinical study, Prexasertib (LY2606368) increased apoptosis of non-small cell lung cancer (NSCLC) cells in culture, and inhibited Chek1 phosphorylation, induced DNA damage, and reduced tumor growth in a NSCLC cell line xenograft model (PMID: 26141948). 26141948
CHEK1 positive colon cancer predicted - sensitive CCT244747 + Gemcitabine Preclinical - Cell line xenograft Actionable In a preclinical study, the combination of CCT244747 and Gemzar (gemcitabine) slowed tumor growth to a greater degree than treatment with either agent alone and decreased Chek1 phosphorylation in colon cancer cell line xenograft models (PMID: 22929806). 22929806